Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Zynex stock
Learn how to easily invest in Zynex stock.
Zynex Inc is a medical distribution business based in the US. Zynex shares (ZYXI) are listed on the NASDAQ and all prices are listed in US Dollars. Zynex employs 768 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Zynex
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ZYXI – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Zynex stock price (NASDAQ: ZYXI)Use our graph to track the performance of ZYXI stocks over time.
Zynex shares at a glance
|Latest market close||$8.42|
|52-week range||$7.59 - $18.69|
|50-day moving average||$10.72|
|200-day moving average||$12.39|
|Wall St. target price||$20.18|
|Dividend yield||N/A (0.88%)|
|Earnings per share (TTM)||$0.26|
Buy Zynex shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Zynex stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Zynex price performance over time
|1 week (2022-01-13)||0.24%|
|1 month (2021-12-20)||-13.91%|
|3 months (2021-10-21)||-31.71%|
|6 months (2021-07-21)||-49.46%|
|1 year (2021-01-21)||-48.41%|
|2 years (2020-01-17)||-13.36%|
|3 years (2019-01-18)||178.14%|
|5 years (2017-01-20)||2,952.94%|
Is Zynex stock undervalued or overvalued?
Valuing Zynex stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zynex's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zynex's P/E ratio
Zynex's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Zynex shares trade at around 32x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Zynex's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $15.3 million.
The EBITDA is a measure of a Zynex's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$115.5 million|
|Operating margin TTM||11.32%|
|Gross profit TTM||$63.4 million|
|Return on assets TTM||10.5%|
|Return on equity TTM||17%|
|Market capitalisation||$326.4 million|
TTM: trailing 12 months
Zynex share dividends
Dividend payout ratio: 35.01% of net profits
Recently Zynex has paid out, on average, around 35.01% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zynex shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Zynex's case, that would currently equate to about $N/A per share.
While Zynex's payout ratio might seem fairly standard, it's worth remembering that Zynex may be investing much of the rest of its net profits in future growth.
Zynex's most recent dividend payout was on 20 January 2022. The latest dividend was paid out to all shareholders who bought their shares by 4 January 2022 (the "ex-dividend date").
Have Zynex's shares ever split?
Zynex's shares were split on a 11:10 basis on 4 January 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 11 shares. This wouldn't directly have changed the overall worth of your Zynex shares – just the quantity. However, indirectly, the new 9.1% lower share price could have impacted the market appetite for Zynex shares which in turn could have impacted Zynex's share price.
Zynex share price volatility
Over the last 12 months, Zynex's shares have ranged in value from as little as $7.5932 up to $18.6891. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zynex's is 0.7734. This would suggest that Zynex's shares are less volatile than average (for this exchange).
Zynex, Inc. , through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers CM-1500, a blood volume monitor device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc.
Zynex in the news
Zynex : Announces Increased Q4 2021 Adjusted EBITDA Estimate and 18% Order Growth - Form 8-K
Zynex Announces Increased Q4 2021 Adjusted EBITDA Estimate and 18% Order Growth
Stocks That Hit 52-Week Lows On Tuesday
Frequently asked questionsWhat percentage of Zynex is owned by insiders or institutions?
Currently 45.749% of Zynex shares are held by insiders and 32.616% by institutions. How many people work for Zynex?
Latest data suggests 768 work at Zynex. When does the fiscal year end for Zynex?
Zynex's fiscal year ends in December. Where is Zynex based?
Zynex's address is: 9555 Maroon Circle, Englewood, CO, United States, 80112 What is Zynex's ISIN number?
Zynex's international securities identification number is: US98986M1036 What is Zynex's CUSIP number?
Zynex's Committee on Uniform Securities Identification Procedures number is: 98986M103
More guides on Finder
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Ask an Expert